Comparative Pharmacology
Head-to-head clinical analysis: JUNEL 1 20 versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNEL 1 20 versus PHILITH.
JUNEL 1/20 vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Ethinyl estradiol is a synthetic estrogen that suppresses gonadotropin release by inhibiting hypothalamic GnRH secretion. Norethindrone acetate is a progestin that suppresses LH surge and thickens cervical mucus to inhibit sperm penetration and alters endometrial development.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days, then repeat.
1 mg orally once daily
None Documented
None Documented
Ethinyl estradiol: 12-24 hours (terminal half-life). Norethindrone: 5-14 hours (terminal half-life). Achieves steady state within 5-7 days.
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Renal: 30-50% (metabolites as glucuronide and sulfate conjugates). Fecal: 20-40% (biliary elimination of metabolites). Unchanged drug: <5% renal.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive